![]() ![]() Participants/materials, setting, methods:Īfter the initial hysteroscopic diagnosis, BMDSC mobilization was performed by granulocyte-CSF injection, then CD133+ cells were isolated through peripheral blood aphaeresis to obtain a mean of 124.39 million cells (range 42-236), which were immediately delivered into the spiral arterioles by catheterization. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and neoangiogenesis were assessed before and 3 and 6 months after cell therapy. There were 18 patients aged 30-45 years with refractory AS or EA were recruited, and 16 of these completed the study. This was a prospective, experimental, non-controlled study. Many therapies have been attempted for these conditions, but none have proved effective. In the first 3 months, autologous cell therapy, using CD133+ BMDSCs in conjunction with hormonal replacement therapy, increased the volume and duration of menses as well as the thickness and angiogenesis processes of the endometrium while decreasing intrauterine adhesion scores.ĪS is characterized by the presence of intrauterine adhesions and EA prevents the endometrium from growing thicker than 5 mm, resulting in menstruation disorders and infertility. 8 Fundaciœn Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics & Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain Instituto Valenciano Infertilidad (IVI) Valencia, Valencia, Spain Department of Obstetrics & Gynecology, Stanford University School of Medicine, Stanford University, Stanford, California Igenomix, Parc Cientific Valencia University, Paterna, Valencia, Spain question:Ĭould cell therapy using autologous peripheral blood CD133+ bone marrow-derived stem cells (BMDSCs) offer a safe and efficient therapeutic approach for patients with refractory Asherman's syndrome (AS) and/or endometrial atrophy (EA) and a wish to conceive?.8 Fundaciœn Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics & Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain Instituto Valenciano Infertilidad (IVI) Valencia, Valencia, Spain Department of Obstetrics & Gynecology, Stanford University School of Medicine, Stanford University, Stanford, California Igenomix, Parc Cientific Valencia University, Paterna, Valencia, Spain 1 Fundaciœn Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics & Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain Instituto Valenciano Infertilidad (IVI) Barcelona, Barcelona, Spain. ![]() 7 Fundaciœn Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics & Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain Instituto Valenciano Infertilidad (IVI) Valencia, Valencia, Spain.6 Department of Radiology, Hospital ClÚnico Universitario/INCLIVA, Valencia, Spain.5 Department of Obstetrics & Gynecology, Hospital ClÚnico Universitario/INCLIVA, Valencia, Spain. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |